- 18 set.- 12:00

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal

Business Wire.
  • Independent central review confirmed responses include 1 complete response, 12 partial responses and 33 stable disease for an objective response rate of 14% and disease control rate of 49%
  • Responses were observed regardless of PD-L1 status, presence of liver metastases or HIV+ status
  • Presentation is available on-demand as part of the ESMO Virtual Congress 2020
  • POD1UM-303/InterAACT 2, a Phase 3 trial evaluating retifanlimab plus chemotherapy in patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal is now open and recruiting patients.
- 18 set.- 09:30

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure

Business Wire.
  • Sigfox, the global 0G network and cloud provider for industrial data, announces a new strategic alliance with Cube Infrastructure Managers.
  • Cube Infrastructure Managers brings together the Sigfox 0G network operators in Germany, Austria, Switzerland and Liechtenstein, through the acquisition of a majority stake in Heliot Europe and the acquisition of Sigfox Germany.
  • This transaction will accelerate the deployment of IoT infrastructure, which is essential to the competitiveness and sustainable development of the European economy.
- 18 set.- 07:00

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months

Business Wire.
  • Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs
  • These results show no new safety signals associated with this increased dose regimen, potentially delaying the need for additional, more toxic second-line therapies
  • The incidence of NETs is increasing, and are now among the fastest growing class of cancers worldwide, accounting for around 2% of all cancers1

 

- 18 set.- 07:00

Vifor Pharma Group Announces Successful Sale of OM Pharma

Business Wire.
  • Vifor Pharma to sell 100% of OM Pharma to Optimus Holding Ltd. for a consideration of MCHF 435
  • In addition Vifor Pharma obtains an earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity which could increase the total transaction value in excess of MCHF 500
  • Closure of the transaction is expected within 30 days
  • Divestment strengthens Vifor Pharma’s focus on becoming the global leader in iron deficiency, nephrology and cardio-renal therapies
- 17 set.- 14:00

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

Business Wire.
  • First clinical study to evaluate novel combination blocking KRAS G12C and its activator SOS1 to potentially increase the therapeutic benefit for lung and colorectal cancer patients
  • Study is based on preclinical evidence suggesting synergistic effect of KRAS G12C and SOS1 inhibition 

Video Economia

Vai alla rubrica Risparmio e Investimenti
Vai al sito: ANSA Professioni


Vai al sito: L'Agenda Economica Finanziaria e Rassegna Stampa dell'ANSA
Vai alla rubrica: Pianeta Camere
Vai alla rubrica: Agrimercati
Vai alla rubrica: PMI

Real Estate


Modifica consenso Cookie